The Immune Revolution: A Case for Priming, Not Checkpoint

Ahonen, 2004, Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN, J. Exp. Med., 199, 775, 10.1084/jem.20031591 Ahonen, 2008, Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines, Blood, 111, 3116, 10.1182/blood-2007-09-114371 Aiello, 2016, Metastatic progression is associated with dynamic changes in the local microenvironment, Nat. Commun., 7, 12819, 10.1038/ncomms12819 Albert, 1998, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392, 86, 10.1038/32183 Aspord, 2007, Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development, J. Exp. Med., 204, 1037, 10.1084/jem.20061120 Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 Bajor, 2015, Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma, Cancer Res., 75, CT137, 10.1158/1538-7445.AM2015-CT137 Bajor, 2014, Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma, Cancer Immunol. Res., 2, 1051, 10.1158/2326-6066.CIR-14-0154 Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462 Balli, 2017, Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer, Clin. Cancer Res., 23, 3129, 10.1158/1078-0432.CCR-16-2128 Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443 Beatty, 2013, A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, Clin. Cancer Res., 19, 6286, 10.1158/1078-0432.CCR-13-1320 Beatty, 2015, Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages, Gastroenterology, 149, 201, 10.1053/j.gastro.2015.04.010 Broomfield, 2009, Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy, J. Immunol., 182, 5217, 10.4049/jimmunol.0803826 Broz, 2014, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity, Cancer Cell, 26, 938, 10.1016/j.ccell.2014.11.010 Byrne, 2016, CD40 stimulation obviates innate sensors and drives T cell immunity in cancer, Cell Rep., 15, 2719, 10.1016/j.celrep.2016.05.058 Carpenter, 2009, Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation, J. Transl. Med., 7, 93, 10.1186/1479-5876-7-93 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Ciampricotti, 2012, Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system, Nat. Med., 18, 344, 10.1038/nm.2652 Ciampricotti, 2011, Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system, J. Pathol., 224, 56, 10.1002/path.2837 Clark, 2007, Dynamics of the immune reaction to pancreatic cancer from inception to invasion, Cancer Res., 67, 9518, 10.1158/0008-5472.CAN-07-0175 Coughlin, 2004, RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy, Blood, 103, 2046, 10.1182/blood-2003-07-2379 Coussens, 2013, Neutralizing tumor-promoting chronic inflammation: a magic bullet?, Science, 339, 286, 10.1126/science.1232227 Dahan, 2016, Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcgammaR engagement, Cancer Cell, 29, 820, 10.1016/j.ccell.2016.05.001 Demaria, 2015, Role of local radiation therapy in cancer immunotherapy, JAMA Oncol., 1, 1325, 10.1001/jamaoncol.2015.2756 DeNardo, 2009, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16, 91, 10.1016/j.ccr.2009.06.018 Duan, 2014, Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity, J. Exp. Med., 211, 2231, 10.1084/jem.20141308 DuPage, 2012, Expression of tumour-specific antigens underlies cancer immunoediting, Nature, 482, 405, 10.1038/nature10803 Durai, 2016, Functions of murine dendritic cells, Immunity, 45, 719, 10.1016/j.immuni.2016.10.010 Engelhardt, 2012, Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells, Cancer Cell, 21, 402, 10.1016/j.ccr.2012.01.008 Evans, 2016, Lack of immunoediting in murine pancreatic cancer reversed with neoantigen, JCI Insight, 1, 10.1172/jci.insight.88328 Feig, 2013, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer, Proc. Natl. Acad. Sci. USA, 110, 20212, 10.1073/pnas.1320318110 Fukunaga, 2004, CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma, Pancreas, 28, e26, 10.1097/00006676-200401000-00023 Gabrilovich, 2004, Mechanisms and functional significance of tumour-induced dendritic-cell defects, Nat. Rev. Immunol., 4, 941, 10.1038/nri1498 Gandhi, 2015, Awakening the immune system with radiation: optimal dose and fractionation, Cancer Lett., 368, 185, 10.1016/j.canlet.2015.03.024 Grewal, 1997, The CD40 ligand. At the center of the immune universe?, Immunol. Res., 16, 59, 10.1007/BF02786323 Gunderson, 2016, Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer, Cancer Discov., 6, 270, 10.1158/2159-8290.CD-15-0827 Harding, 2017, Mitotic progression following DNA damage enables pattern recognition within micronuclei, Nature, 548, 466, 10.1038/nature23470 Heath, 2001, Cross-presentation, dendritic cells, tolerance and immunity, Annu. Rev. Immunol., 19, 47, 10.1146/annurev.immunol.19.1.47 Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 Ino, 2013, Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer, PLoS One, 8, e55146, 10.1371/journal.pone.0055146 Ino, 2013, Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer, Br. J. Cancer, 108, 914, 10.1038/bjc.2013.32 Johnson, 2017, First in human study with the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors, J. Immunother. Cancer, 5, 89 Johnson, 2015, Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study, Clin. Cancer Res., 21, 1321, 10.1158/1078-0432.CCR-14-2355 Kraman, 2011, Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha, Science, 330, 827, 10.1126/science.1195300 Lanzavecchia, 1998, Immunology. Licence to kill, Nature, 393, 413, 10.1038/30845 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Li, 2011, Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies, Science, 333, 1030, 10.1126/science.1206954 Lutz, 2014, Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy, Oncoimmunology, 3, e962401, 10.4161/21624011.2014.962401 Matsushita, 2012, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, 482, 400, 10.1038/nature10755 McDonnell, 2017, Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters, BMC Cancer, 17, 417, 10.1186/s12885-017-3403-5 Messmer, 2005, CD154 gene therapy for human B-cell malignancies, Ann. N. Y. Acad. Sci., 1062, 51, 10.1196/annals.1358.008 Ngiow, 2016, Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor, Cancer Res., 76, 6266, 10.1158/0008-5472.CAN-16-2141 Nowak, 2015, A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma, Ann. Oncol., 26, 2483, 10.1093/annonc/mdv387 Nowak, 2003, Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors, Cancer Res., 63, 4490 Poschke, 2016, Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma, Oncoimmunology, 5, e1240859, 10.1080/2162402X.2016.1240859 Rech, 2018, Tumor immunity and survival as a function of alternative neopeptides in human cancer, Cancer Immunol. Res., 10.1158/2326-6066.CIR-17-0559 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Remer, 2017, The use of anti-CD40 mAb in cancer, Curr. Top. Microbiol. Immunol., 405, 165 Richman, 2014, Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer, Cancer Immunol. Res., 2, 19, 10.1158/2326-6066.CIR-13-0152 Roberts, 2016, Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma, Cancer Cell, 30, 324, 10.1016/j.ccell.2016.06.003 Rüter, 2010, Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors, Cancer Biol. Ther., 10, 983, 10.4161/cbt.10.10.13251 Salmon, 2016, Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition, Immunity, 44, 924, 10.1016/j.immuni.2016.03.012 Sanchez-Paulete, 2016, Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells, Cancer Discov., 6, 71, 10.1158/2159-8290.CD-15-0510 Sandin, 2014, Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer, Cancer Immunol. Res., 2, 80, 10.1158/2326-6066.CIR-13-0067 Scarlett, 2009, In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells, Cancer Res., 69, 7329, 10.1158/0008-5472.CAN-09-0835 Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 Schultze, 1997, CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy, J. Clin. Invest., 100, 2757, 10.1172/JCI119822 Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122 Sharma, 2015, The future of immune checkpoint therapy, Science, 348, 56, 10.1126/science.aaa8172 Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 68, 7, 10.3322/caac.21442 Spranger, 2017, Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy, Cancer Cell, 31, 711, 10.1016/j.ccell.2017.04.003 Stromnes, 2015, T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma, Cancer Cell, 28, 638, 10.1016/j.ccell.2015.09.022 Teng, 2015, Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res., 75, 2139, 10.1158/0008-5472.CAN-15-0255 Uno, 2006, Eradication of established tumors in mice by a combination antibody-based therapy, Nat. Med., 12, 693, 10.1038/nm1405 van Kooten, 2000, CD40-CD40 ligand, J. Leukoc. Biol., 67, 2, 10.1002/jlb.67.1.2 van Mierlo, 2002, CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity, Proc. Natl. Acad. Sci. USA, 99, 5561, 10.1073/pnas.082107699 Verbrugge, 2012, Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies, Cancer Res., 72, 3163, 10.1158/0008-5472.CAN-12-0210 Vonderheide, 2007, Prospect of targeting the CD40 pathway for cancer therapy, Clin. Cancer Res., 13, 1083, 10.1158/1078-0432.CCR-06-1893 Vonderheide, 2013, Inflammatory networks and immune surveillance of pancreatic carcinoma, Curr. Opin. Immunol., 25, 200, 10.1016/j.coi.2013.01.006 Vonderheide, 2013, Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors, Oncoimmunology, 2, e23033, 10.4161/onci.23033 Vonderheide, 2001, Phase I study of recombinant human CD40 ligand in cancer patients, J. Clin. Oncol., 19, 3280, 10.1200/JCO.2001.19.13.3280 Vonderheide, 2007, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, J. Clin. Oncol., 25, 876, 10.1200/JCO.2006.08.3311 Vonderheide, 2013, Agonistic CD40 antibodies and cancer therapy, Clin. Cancer Res., 19, 1035, 10.1158/1078-0432.CCR-12-2064 White, 2013, FcgammaRIIB controls the potency of agonistic anti-TNFR mAbs, Cancer Immunol. Immunother., 62, 941, 10.1007/s00262-013-1398-6 White, 2015, Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies, Cancer Cell, 27, 138, 10.1016/j.ccell.2014.11.001 White, 2011, Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody, J. Immunol., 187, 1754, 10.4049/jimmunol.1101135 Winograd, 2015, Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma, Cancer Immunol. Res., 3, 399, 10.1158/2326-6066.CIR-14-0215 Wormann, 2014, The immune network in pancreatic cancer development and progression, Oncogene, 33, 2956, 10.1038/onc.2013.257 Zamarin, 2014, Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy, Sci. Transl. Med., 6, 226ra32, 10.1126/scitranslmed.3008095 Zippelius, 2015, Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment, Cancer Immunol. Res., 3, 236, 10.1158/2326-6066.CIR-14-0226